Uses of Viibryd

Viibryd has the main ingredient Vilazodone, which belongs to the group of psychotropic drugs. Viibryd is commonly used in the treatment of major depression (MDD). Understanding the basic information such as ingredients, indications, contraindications, dosage and side effects of Viibryd will help patients improve treatment results.

Viibryd drug is prepared in different strength tablets such as 20, 40, 60 and 80 mg, with main ingredients including:
Active ingredient: Vilazodone (in the form of Vilazodone hydrochloride). Excipients: Lactose monohydrate, Magnesium stearate, Microcrystalline cellulose, Colloidal silicon dioxide, Titanium dioxide, Polyvinyl alcohol, Titanium dioxide, Talc powder, Polyethylene glycol, FD&C Yellow, FD&C Blue and FD&C Red just enough for 1 tablet. Pharmacodynamics:
Currently, scientists still do not understand the mechanism of antidepressant action of Vilazodone hydrochloride, but some evidence suggests that this mechanism involves selective inhibition of Serotonin reuptake from there. Serotonergic activity in the central nervous system is enhanced. In addition, the active ingredient Vilazodone hydrochloride is also an agonist at Serotonergic 5-HT1A receptors, however data on this effect on Serotonergic transmission and the role of this process in antidepressant effects are available. The sensitivity of Vilazodone hydrochloride is still not well understood.

Viibryd is indicated for the treatment of patients with major depressive disorder (MDD). Major depressive disorder (MDD) consists of one or more prominent and daily episodes for at least 2 weeks where symptoms of depression or frustration interfere with normal daily functioning and includes at least 5 of the following 9 symptoms:
Depressed mood; Loss of interest in normal activities; Changes in weight and/and appetite; Drowsiness or insomnia; Mental stimulation or mental retardation; Tired; Feelings of worthlessness or guilt; Decreased ability to concentrate or slow down thinking; Suicide intention.

Hypersensitivity to any component of Viibryd. History of allergy to other drugs containing Vilazodone hydrochloride. People who are being treated with Monoamine Oxidase Inhibitors (MAOIs) or taking MAOIs for at least 14 days before taking Viibryd. Pregnant women or women who are breastfeeding. Elderly or children. People with impaired liver function, severe kidney function.

It is recommended to use Viibryd with meals.
Dosage
7 days first: Take 10 mg / time / day. The next 7 days: Take 20 mg/time/day. Maintenance dose: Oral 40 mg/time/day.

Treatment with Viibryd with high dose or long term, can cause side effects such as:
Psychiatric: Insomnia, frequent nightmares, restlessness, panic attacks, manic episodes. Nervous: Sedative effect, headache, migraine, dizziness, vertigo, neurodevelopmental disorder, paresthesia, limb tremor. Visual disturbances: Dry eyes, blurred vision, cataracts. Cardiovascular: Chest pain, palpitations, ventricular extrasystoles. Digestive disorders: Decreased taste, dry mouth, dyspepsia, flatulence, nausea, vomiting, diarrhea, gastroenteritis. Urinary: Blood in urine. Genitourinary: Slow ejaculation, decreased sex drive, erectile dysfunction. Skin and soft tissues: Excessive sweating at night, allergic manifestations on the skin such as skin rash, angioedema, urticaria, itching. Body as a whole: Fatigue, asthenia, anaphylaxis, multi-organ failure. The drug should be stopped when detecting the above symptoms or other abnormalities after taking Viibryd and promptly inform the treating doctor about the use of Viibryd or immediately go to the nearest medical facility for timely treatment. .
Note the use of Viibryd drug in the following subjects:
For patients with major depressive disorder (MDD) who have been treated with Viibryd, some cases have been recorded with symptoms of depression become more severe and may present with suicidal ideation and behavior or other unusual changes in behavior. Therefore, all cases being treated with Viibryd during the first few months of the course or at times when the dose is changed, or the dose is increased or decreased, should be closely and closely monitored for timely treatment. detect the above abnormalities in time for timely treatment. Viibryd should be used with caution in people with a history or current history of neuroleptic malignant syndrome (NMS), Serotonin syndrome, convulsions, coagulopathy, abnormal bleeding, hyponatremia, confusion. Mania/Hypomania bipolar disorder. Pregnant women: The US Food and Drug Administration (FDA) classifies Vilazodone hydrochloride active ingredient in Viibryd as Group C, which has evidence of a risk in pregnancy. Therefore, Viibryd is contraindicated in pregnant women. Lactation: Studies have shown that the active ingredient Vilazodone hydrochloride in Viibryd can pass into breast milk, but its effects on breastfed infants are not well understood. Therefore, the use of Viibryd should only be considered if the potential benefit outweighs the potential risk to the child. Drivers or machine operators may experience some neurological or visual dysfunction after using Viibryd, so it is not recommended to take Viibryd before entering work.

Interactions with other drugs:
Avoid combining Viibryd with other drugs that can affect the Serotonergic neurotransmitter system such as: MAOIs, SSRIs, SNRIs, Triptans, Tramadol, Buspirone, Tryptophan. Avoid using the following combination of Vilazodone because it can cause clotting disorders, increasing the risk of abnormal bleeding: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Aspirin. Warfarin. Above is the necessary information about the composition, uses, dosage and precautions of Viibryd. Patients and family members should carefully read the instructions on the Viibryd package, and consult with the treating doctor before deciding to use.